CXCL10/XCL1 fusokine elicits in vitro and in vivo chemotaxis

详细信息    查看全文

• 作者：Yessica E. Sanchez-Lugo (1)
  Jose J. Perez-Trujillo (1)
  Yolanda Gutierrez-Puente (2)
  Aracely Garcia-Garcia (1)
  Humberto Rodriguez-Rocha (1)
  Oralia Barboza-Quintana (3)
  Gerardo E. Mu帽oz-Maldonado (4)
  Odila Saucedo-Cardenas (1) (5)
  Roberto Montes de Oca-Luna (1)
  Maria J. Loera-Arias (1)
  
  1. Departamento de Histologia ; Facultad de Medicina ; Universidad Autonoma de Nuevo Leon (UANL) ; Madero y Aguirre Peque帽o s/n Mitras Centro ; CP ; 64665 ; Monterrey ; NL ; Mexico
  2. Departamento de Bioquimica ; Facultad de Ciencias Biologicas ; Universidad Autonoma de Nuevo Leon (UANL) ; CP ; 66450 ; Monterrey ; NL ; Mexico
  3. Servicio de Anatomia Patologica y Citopatologia ; Hospital Universitario 鈥淒r. Jose Eleuterio Gonzalez鈥?de la Facultad de Medicina ; Universidad Autonoma de Nuevo Leon (UANL) ; CP ; 64665 ; Monterrey ; NL ; Mexico
  4. Servicio de Cirugia General ; Hospital Universitario 鈥淒r. Jose Eleuterio Gonz谩lez鈥?de la Facultad de Medicina ; Universidad Autonoma de Nuevo Leon (UANL) ; CP ; 64665 ; Monterrey ; NL ; Mexico
  5. Division de Gen茅tica ; Centro de Investigacion Biomedica del Noreste ; Instituto Mexicano del Seguro Social (IMSS) ; CP ; 64665 ; Monterrey ; NL ; Mexico
  
• 关键词：Adenovirus ; Cancer therapy ; CXCL10 ; Fusokine ; Gene therapy ; Immunotherapy ; Interferon ; gamma ; inducible protein 10 ; Lymphotactin
• 刊名：Biotechnology Letters
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：37
• 期：4
• 页码：779-785
• 全文大小：1,953 KB
• 参考文献：1. Cairns, CM, Gordon, JR, Li, F (2001) Lymphotactin expression by engineered myeloma cells drives tumor regression: mediation by CD4+ and CD8+ T cells and neutrophils expressing XCR1 receptor. J Immunol Baltim Md 1950 167: pp. 57-65
  2. Cheng, W-F, Hung, C-F, Chai, C-Y (2001) Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 108: pp. 669-678 CrossRef
  3. Dufour, JH, Dziejman, M, Liu, MT (2002) IFN-纬-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 168: pp. 3195-3204 CrossRef
  4. Gattinoni, L, Powell, DJ, Rosenberg, SA, Restifo, NP (2006) Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6: pp. 383-393 CrossRef
  5. Gomez-Gutierrez, JG, Elpek, KG, Oca-Luna, RM (2007) Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother CII 56: pp. 997-1007 CrossRef
  6. Gooden, MJM, Bock, GH, Leffers, N (2011) The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 105: pp. 93-103 CrossRef
  7. Huang, H, Xiang, J (2004) Synergistic effect of lymphotactin and interferon gamma-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors. Int J Cancer J Int Cancer 109: pp. 817-825 CrossRef
  8. K盲llberg, M, Wang, H, Wang, S (2012) Template-based protein structure modeling using the RaptorX web server. Nat Protoc 7: pp. 1511-1522 CrossRef
  9. Lei, Y, Takahama, Y (2012) XCL1 and XCR1 in the immune system. Microbes Infect Inst Pasteur 14: pp. 262-267 CrossRef
  10. Proudfoot, AEI (2002) Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2: pp. 106-115 CrossRef
  11. Raman, D, Baugher, PJ, Thu, YM, Richmond, A (2007) Role of chemokines in tumor growth. Cancer Lett 256: pp. 137-165 CrossRef
  12. Russell, HV, Strother, D, Mei, Z (2007) Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother Hagerstown Md 1997 30: pp. 227-233
  13. Wang, P, Yang, X, Xu, W (2010) Integrating individual functional moieties of CXCL10 and CXCL11 into a novel chimeric chemokine leads to synergistic antitumor effects: a strategy for chemokine-based multi-target-directed cancer therapy. Cancer Immunol Immunother CII 59: pp. 1715-1726 CrossRef
  14. Wang, X, Lu, X-L, Zhao, H-Y (2013) A novel recombinant protein of IP10-EGFRvIIIscFv and CD8(+) cytotoxic T lymphocytes synergistically inhibits the growth of implanted glioma in mice. Cancer Immunol Immunother CII 62: pp. 1261-1272 CrossRef
  15. Wansom, D, Light, E, Thomas, D (2012) Infiltrating lymphocytes and human papillomavirus-16 associated oropharynx cancer. Laryngoscope 122: pp. 121-127 CrossRef
  16. Wennerberg, E, Kremer, V, Childs, R, Lundqvist, A (2014) CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo. Cancer Immunol Immunother CII.
  17. Williams, P, Galipeau, J (2011) GM-CSF鈥揵ased fusion Cytokines as ligands for immune modulation. J Immunol 186: pp. 5527-5532 CrossRef
  18. Yang, X, Chu, Y, Wang, Y (2006) Targeted in vivo expression of IFN-gamma-inducible protein 10 induces specific antitumor activity. J Leukoc Biol 80: pp. 1434-1444 CrossRef
  19. Zhang, J, Zhou, Z, Wang, C (2011) Reduced tumorigenesis of EG7 after interleukin-10 gene transfer and enhanced efficacy in combination with intratumorally injection of adenovirus-mediated lymphotactin and the underlying mechanism. Cancer Immunol Immunother CII 60: pp. 559-573 CrossRef
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Life Sciences
  Microbiology
  Biotechnology
  Applied Microbiology
  Biochemistry
  
• 出版者：Springer Netherlands
• ISSN：1573-6776

文摘

Fusokines are proteins formed by the fusion of two cytokines. They have greater bioavailability and therapeutic potential than individual cytokines or a combination of different cytokines. Interferon-gamma-inducible protein 10 (CXCL10) and lymphotactin (XCL1) are members of the chemotactic family of cytokines, which induce tumor regression by eliciting immune-system cell chemotaxis. We engineered a replication-deficient adenoviral system expressing CXCL10/XCL1 fusokine (Ad FIL) and assessed its chemotactic response in vitro and in vivo. The CXCL10/XCL1 fusokine elicited a greater chemotactic effect in IL-2 stimulated lymphocytes than individual or combined cytokines in vitro. CXCL10/XCL1 fusokine biological activity was demonstrated in vivo by intratumoral chemoattraction of CXCR3+ cells. Thus, this novel CXCL10/XCL1 fusokine may represent a potential tool for gene therapy treatment of cancer and other illnesses that require triggering immune-system cell recruitment.